446 related articles for article (PubMed ID: 19565214)
1. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.
Hemkens LG; Grouven U; Bender R; Günster C; Gutschmidt S; Selke GW; Sawicki PT
Diabetologia; 2009 Sep; 52(9):1732-44. PubMed ID: 19565214
[TBL] [Abstract][Full Text] [Related]
2. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.
Colhoun HM;
Diabetologia; 2009 Sep; 52(9):1755-65. PubMed ID: 19603149
[TBL] [Abstract][Full Text] [Related]
3. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study.
Ruiter R; Visser LE; van Herk-Sukel MP; Coebergh JW; Haak HR; Geelhoed-Duijvestijn PH; Straus SM; Herings RM; Stricker BH
Diabetologia; 2012 Jan; 55(1):51-62. PubMed ID: 21956710
[TBL] [Abstract][Full Text] [Related]
4. Combined randomised controlled trial experience of malignancies in studies using insulin glargine.
Home PD; Lagarenne P
Diabetologia; 2009 Dec; 52(12):2499-506. PubMed ID: 19756478
[TBL] [Abstract][Full Text] [Related]
5. Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database.
Blin P; Lassalle R; Dureau-Pournin C; Ambrosino B; Bernard MA; Abouelfath A; Gin H; Le Jeunne C; Pariente A; Droz C; Moore N
Diabetologia; 2012 Mar; 55(3):644-53. PubMed ID: 22222504
[TBL] [Abstract][Full Text] [Related]
6. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.
Jonasson JM; Ljung R; Talbäck M; Haglund B; Gudbjörnsdòttir S; Steineck G
Diabetologia; 2009 Sep; 52(9):1745-54. PubMed ID: 19588120
[TBL] [Abstract][Full Text] [Related]
7. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis.
Dejgaard A; Lynggaard H; Råstam J; Krogsgaard Thomsen M
Diabetologia; 2009 Dec; 52(12):2507-12. PubMed ID: 19838665
[TBL] [Abstract][Full Text] [Related]
8. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients.
Mannucci E; Monami M; Balzi D; Cresci B; Pala L; Melani C; Lamanna C; Bracali I; Bigiarini M; Barchielli A; Marchionni N; Rotella CM
Diabetes Care; 2010 Sep; 33(9):1997-2003. PubMed ID: 20551014
[TBL] [Abstract][Full Text] [Related]
9. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
[TBL] [Abstract][Full Text] [Related]
10. Insulin glargine: a systematic review of a long-acting insulin analogue.
Wang F; Carabino JM; Vergara CM
Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
[TBL] [Abstract][Full Text] [Related]
11. [Switching of NPH insulin to glargine therapy in a cohort of diabetic patients: observational study].
Maia FF; Melo FJ; Araújo IM; Araújo LR
Arq Bras Endocrinol Metabol; 2007 Apr; 51(3):426-30. PubMed ID: 17546241
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of insulin glargine on the risk of breast cancer.
Suissa S; Azoulay L; Dell'Aniello S; Evans M; Vora J; Pollak M
Diabetologia; 2011 Sep; 54(9):2254-62. PubMed ID: 21614572
[TBL] [Abstract][Full Text] [Related]
13. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.
Habel LA; Danforth KN; Quesenberry CP; Capra A; Van Den Eeden SK; Weiss NS; Ferrara A
Diabetes Care; 2013 Dec; 36(12):3953-60. PubMed ID: 24170756
[TBL] [Abstract][Full Text] [Related]
14. Insulin glargine and incidence of cancer--an ongoing debate.
Hermanns N; Kulzer B
J Diabetes Sci Technol; 2010 Mar; 4(2):497-8. PubMed ID: 20307414
[No Abstract] [Full Text] [Related]
15. Insulin glargine use and short-term incidence of malignancies - a three-year population-based observation.
Ljung R; Talbäck M; Haglund B; Jonasson JM; Gudbjörnsdòttir S; Steineck G
Acta Oncol; 2011 Jun; 50(5):685-93. PubMed ID: 21506898
[TBL] [Abstract][Full Text] [Related]
16. Risk of cancer in patients receiving insulin glargine.
Dawson LK; Hamilton LA
Am J Health Syst Pharm; 2010 Dec; 67(23):2025-31. PubMed ID: 21098374
[TBL] [Abstract][Full Text] [Related]
17. Risk of breast cancer by individual insulin use: an international multicenter study.
Grimaldi-Bensouda L; Cameron D; Marty M; Barnett AH; Penault-Llorca F; Pollak M; Charbonnel B; Riddle M; Mignot L; Boivin JF; Khachatryan A; Rossignol M; Bénichou J; Alpérovitch A; Abenhaim L;
Diabetes Care; 2014; 37(1):134-43. PubMed ID: 23949559
[TBL] [Abstract][Full Text] [Related]
18. Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues.
Simon D
Diabetologia; 2010 Jan; 53(1):204-5. PubMed ID: 19859691
[No Abstract] [Full Text] [Related]
19. [Increased risk of cancer using insulin and insulin analogues?].
Schäffler A
MMW Fortschr Med; 2010 Sep; 152(36):39-41. PubMed ID: 21192466
[No Abstract] [Full Text] [Related]
20. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
